0M, trading at $4.30 on the NASDAQ. This SniperIQ fundamentals page covers Minerva Neurosciences's valuation, profitability (net margin 0.0%), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap
0M
Net Margin0.0%

Full research coverage

Frequently Asked Questions

What is Minerva Neurosciences's market cap?

Minerva Neurosciences (NERV) has a market capitalization of approximately

0M, trading at $4.30 on the NASDAQ. Market cap moves with the live share price.

How profitable is Minerva Neurosciences?

Minerva Neurosciences runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

Does Minerva Neurosciences pay a dividend?

Minerva Neurosciences does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Minerva Neurosciences financially healthy?

Minerva Neurosciences carries a debt-to-equity ratio of -0.26x and a current ratio of 17.65x, with a market beta of -0.18. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Minerva Neurosciences a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Minerva Neurosciences (NERV) the key facts are: market cap

0M, 52-week range 1.76-12.46. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Minerva Neurosciences's full fundamentals live

Get Minerva Neurosciences's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.